Literature DB >> 3366854

Combination ELISAs for antiviral antibodies in CSF and serum in patients with neurological symptoms and in healthy controls.

T Mathiesen1, E Fridell, S Fredrikson, A Linde, V A Sundqvist, D Edler, B Wahren.   

Abstract

A combination enzyme-linked immunosorbent assay (ELISA) was designed to improve the estimation of serum: cerebrospinal fluid (CSF) antiviral IgG ratios. Microplate wells were coated with five different virus antigens. Serum and CSF from 66 patients referred for CSF serology and from 21 healthy controls were studied. In a comparison with serum: CSF IgG titre ratios, absorbance ratios were found to be suitable for the evaluation of intrathecal antiviral IgG synthesis. A slight blood-brain barrier (BBB) disturbance affected only the passage of albumin over the BBB, whereas a more pronounced BBB defect resulted in increased IgG levels in the CSF. Intrathecal antiviral IgG synthesis was demonstrated in 15 patients with viral CNS infections or inflammatory diseases. Very high serum: CSF antiviral IgG titre ratios and absorbance ratios, found in six patients, were interpreted as signs of diminished IgG passage over the BBB due to impaired CSF circulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3366854     DOI: 10.1016/0166-0934(88)90160-7

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  4 in total

1.  Antiviral IgM and IgG subclasses in varicella zoster associated neurological syndromes.

Authors:  T Mathiesen; A Linde; E Olding-Stenkvist; B Wahren
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

2.  Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system.

Authors:  T Mathiesen; H von Holst; S Fredrikson; G Wirsén; B Hederstedt; E Norrby; V A Sundqvist; B Wahren
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849

3.  Specific IgG subclass reactivity in herpes simplex encephalitis.

Authors:  T Mathiesen; A Linde; E Olding-Stenkvist; B Wahren
Journal:  J Neurol       Date:  1988-09       Impact factor: 4.849

Review 4.  Recent progress and considerations for AAV gene therapies targeting the central nervous system.

Authors:  Erik Allen Lykken; Charles Shyng; Reginald James Edwards; Alejandra Rozenberg; Steven James Gray
Journal:  J Neurodev Disord       Date:  2018-05-18       Impact factor: 4.025

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.